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Abstract
Telomeres represent ends of all eukaryotic chromosomes and serve specialized biological
role in maintaining genomic integrity by preventing end fusions and degradation. Vari‐
ous protein complexes associate with telomeres to either protect them from DNA damage
machinery or maintain telomere length homeostasis. These protein complex subunits
cross talk with a variety of cell-signaling components to either maintain telomere integri‐
ty or perform other functions, which are either dependent or independent of telomeres
and/or their telomeric role. Mutations in these protein components lead to the develop‐
ment of various human diseases, such as age-related disorders, which occur mainly due
to telomere dysfunction or cancer development due to telomerase reactivation. This chap‐
ter focuses on the structural and functional aspects of telomeric proteins and their impor‐
tance in human diseases.
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1. Introduction
Human telomeres consist of TTAGGG tandem repeats, which are generally 3–15 kbp in length
[1]. The distal end of telomere has a 3′ single-stranded overhang, which is also termed a G-
rich strand, and it forms a higher order structure (like a lariat) named t-loop [2]. In t-loop, both
strands of the chromosome are joined to an earlier point in the double-stranded DNA by the
3′ strand end invading the strand pair to further form a D-loop. Formation of the D-loop
completes the t-loop, thus establishing a capping structure, which protects chromosomes from
degradation and recombination [3]. Figure 1A shows a schematic representation of telomere
structure. The disruption of t-loop results in telomere dysfunction and induction of DNA
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damage response (DDR) followed by cell cycle arrest [4]. Telomeres are bound by nucleosomes
and a specialized complex known as shelterin, which is composed of six core protein subunits
[5]. Shelterin determines the structure of telomeres. It is implicated in the formation of t-loops
and also regulates the synthesis of telomeric DNA [6]. Additional proteins capable of inter‐
acting with shelterin proteins, such as DNA damage proteins, also play a role in maintaining
telomere length and chromosomal stability [7].
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Figure 1. Schematic representation of telomere end structure (A) and Telomere associated protein complexes (B).
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Telomeres shorten with replication due to two major mechanisms: (A) end-replication problem
and exonuclease-mediated resection in dividing cells, and (B) damage response to reactive
oxygen species in nondividing cells [8].
DNA replication involves simultaneous duplication of antiparallel DNA strands, such that
replication advances in opposite directions, across a leading strand and a lagging strand. On
the leading strand, daughter strand synthesis takes place continuously in the 5′–3′ direction,
whereas on the lagging strand template, DNA synthesis proceeds in the 5′–3′ direction
discontinuously, leading to Okazaki fragments. The leading daughter strand is completely
synthesized until DNA polymerase reaches 5′ end of the leading template. However, a primer
is required for DNA replication to start. At the end of replication, RNA primer occupying the
5′ end of the daughter strand is removed, and it is not possible for the overlapping strand to
be replicated. Due to this, the 5′ end of each antiparallel daughter strand becomes one primer
length shorter. This is referred to as the end-replication problem, which results in chromosome
shortening with each subsequent cell division. Theoretically, it should result in a loss of less
than 10 bp with each replication cycle; however, the rate of loss is much higher and has been
calculated to be 50–200 bp per division [9]. Exonuclease activity degrading the 5′ end is another
major factor, which removes the RNA primer on the lagging strand and thus also leads to the
formation of 3′-end overhang structure [10]. In vitro studies have also suggested the role of
oxidative stress in telomere loss [11]. Correlative and experimental studies have also suggested
links between oxidative damage and telomere loss in vivo [12]. Therefore, telomere length also
serves as a biological clock and marker for chronological ageing. The solution to telomere
shortening is the telomerase enzyme complex, which catalyzes de novo addition of TTAGGG
repeats to chromosome ends, thus preventing telomere attrition [13].
2. Telomere-Associated Protein Complexes (TAPs)
2.1. Shelterin
Shelterin, as the name suggests, provides shelter to the ends of linear chromosomes by
repressing DNA damage-signaling responses, masking telomeres from DNA repair machi‐
nery, and regulating the length of telomeres [7, 14]. Shelterin is a highly specialized complex
comprising six central components namely, TTAGGG repeat-binding factors TRF1 and TRF2,
TRF1-interacting protein (TIN2), protection of telomeres protein (POT1), Pot1-interacting
protein (TPP1), and repressor/activator protein (RAP1) [15]. All shelterin components are
ubiquitously expressed and associated with telomeres throughout the cell division cycle. The
complete abrogation of all shelterin subunits (except RAP1) in mice results in embryonic
lethality, thereby implicating their essential roles in development [16].
TRF1
TRF1 was the first shelterin complex subunit to be discovered that specifically associates with
double-stranded telomeric DNA, mainly as a dimer through its TRF homology domain.
Recently, it has been shown that TRF1 efficiently associates with telomeric DNA in nucleoso‐
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mal context and is capable of remodeling telomeric nucleosomal arrays [17]. TRF1 interacts
with TIN2 in the shelterin complex as shown in Figure 1B. It also functions as a negative
regulator of telomere length in telomerase-positive cells. In addition, some reports have
demonstrated that it is essential for survival independent of its telomere length regulatory
activity [18]. TRF1 genome-wide binding analysis revealed that it exclusively localizes at
telomeres under normal conditions as well as under extreme telomere shortening unlike other
shelterin members which have extra telomeric roles [19]. TRF1 has also been shown to assist
Aurora-B recruitment to centromeres, thus contributing to appropriate chromosome segrega‐
tion and maintenance of genomic integrity [20].
TRF2
TRF2 is highly similar to TRF1 in terms of protein sequence except that the N-terminal domain
in TRF2 is acidic while that in TRF1 is rich in glycine and arginine residues (forming GAR
domain). It possesses TRF homology domain, which mediates its dimerization. This N-
terminal domain of TRF1 and TRF2 has been shown to regulate their ability to condense
telomeric DNA [21]. TRF2 has been proposed to stabilize the t-loop by invasion of the upstream
TTAGGG double-stranded region [22]. TRF2 has also been shown to bind at internal genomic
regions, mainly at TTAGGG repeats referred to as interstitial telomeric sequences (ITSs) [23,
24]. Recent evidence suggests the role of TRF2 in the formation of novel chromosome end
structures, which involve telomeres interacting with nontelomeric DNA, forming long-range
chromosome loop that encompasses several megabases of chromatin and are known as
interstitial telomeric loops (ITLs) [25]. Telomere-bound TRF2 is necessary to suppress the
ataxia telangiectasia mutated (ATM)-dependent DNA damage response pathway [26] and the
nonhomologous end joining (NHEJ) DNA repair pathway, thus playing a major role in
protecting chromosome ends [9]. TRF2 also assists telomere replication by limiting resolvase
activities leading to accurate repair of stalled forks [27]. It has been demonstrated that both
TRF1 and TRF2 are modified post-translationally; however, the physiological relevance of
these modifications is not yet completely understood [7].
TIN2
TIN2 (encoded by TINF2) associates with both TRF1 and TRF2, thus forming a bridge that
connects the double-stranded telomeric DNA-binding proteins to those bound to single-
stranded telomeric overhang region [28, 29]. A recent study by Frank et al demonstrates that
TIN2 facilitates the recruitment of telomerase to telomeres [30]. In this study, the authors
discovered a novel mutation in TINF2 gene (which encodes TIN2 protein) and used novel
functional assays to demonstrate a direct role for TIN2 in regulating telomere length through
telomerase. This role is completely independent of its role in telomere protection.
TPP1
TPP1 interacts with TIN2 and POT1 through its carboxyl terminus and central domain,
respectively [31-33]. Structurally, TPP1 possesses four domains, namely, OB (oligonucleotide/
oligosaccharide-binding fold), RD (POT1 recruitment domain), S/T (serine-rich region), and
TID (TIN2-interacting domain). It has been demonstrated that TPP1 recruits POT1 to telomeres
[34, 35]. In addition, TPP1 has been shown to contain telomerase-interacting domain, suggest‐
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ing a role for TPP1 in the recruitment of telomerase to chromosome ends [36]. Interestingly, it
has been shown that TPP1–POT1 interacts with N-terminal region of telomerase protein
subunit TERT (telomerase reverse transcriptase), while TPP1 alone is also capable of interact‐
ing with C-terminal TERT residues through TPP1-OB domain [37]. TPP1-OB domain has been
shown to contain a TEL patch (TPP1 glutamate (E)- and leucine (L)-rich patch), which mediates
telomerase recruitment and processivity independent of its role in telomere capping [38]. In
human stem cells, it has been further proven that TPP1 indeed mediates recruitment and
activation of telomerase and telomere length homeostasis [39].
POT1
POT1 interacts with TRF1 complex via protein–protein interaction with TPP1, and this
interaction is believed to affect its loading on the single-stranded TTAGGG telomeric repeat
[40]. POT1 has been predicted to associate with telomeric sequences at t-loop as well as D-loop
through its OB-fold domains [32]. POT1 serves a fundamental role in telomere length regula‐
tion, since it functions as a terminal transducer of telomere length control [40]. POT1–TPP1
complex has been shown to increase RAP (consecutive repeats that telomerase can add to
telomere before dissociating) with minimal effect on telomerase activity [41]. Further, POT1–
TPP1 has been shown to reduce the dissociation rate of telomerase from its telomeric substrate
and assist in the translocation step [42].
RAP1
RAP1 associates with TRF2 and thus localizes to telomeres. As a component of the shelterin
complex, it is dependent on TRF2 [43, 44]. RAP1 has been shown to be indispensable for
telomere function in mouse and human systems [45, 46]. Further, RAP1 has been shown to
possess extra telomeric roles that will be described in later part of this chapter.
2.2. Telomerase complex
Telomeres in human somatic cells shorten with each replication cycle due to end-replication
problem consequently leading to genomic instability and cell death. Telomerase elongates
telomeres and thus maintain their replicative potential. The minimal components of telomer‐
ase are a catalytic protein subunit termed as telomerase reverse transcriptase (TERT) and an
RNA template known as Terc (TR) [47]. Telomerase catalyzes the addition of TTAGGG
sequences to the ends of the chromosomes during each replication cycle, thus preventing
telomere attrition and maintaining genomic integrity. Telomerase activity is detected pre‐
dominantly in stem cells and cancer cells [48]. In normal somatic cells, telomerase activity is
almost undetectable, consequently leading to shortened telomeres, which limit their life span.
Furthermore, while TR is highly expressed in all the cell types, the levels of TERT are highly
regulated at transcriptional level [49]. In somatic cells, TERT is transcriptionally turned off
while stem cells display high expression of TERT, resulting in high telomerase activity. Ninety
percent of cancer cells reactivate TERT expression either by mutation in TERT promoter or by
activating oncogenic transcription factors such as NF-κB, MYC, and β-catenin that are known
to activate TERT transcription [50]. This reactivation of TERT confers cancer cells with
unlimited replicative potential. Distinct from its telomeric function, TERT has also been shown
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to cross talk with various signaling pathways and impart several additional functions to cancer
cells [51].
Terc (TR)
Mature human TR is a small noncoding RNA consisting of 451 nucleotides and serves as a
template for de novo telomeric repeat synthesis by telomerase. Structurally, it is subdivided
into four domains namely the pseudoknot domain, the CR4-CR5 domain, the CR7, and
H/ACA domain [52]. These domains perform various functions including RNA binding,
dimerization, and recruitment of telomerase to telomeres. The pseudoknot domain and the
CR4/5 domain along with TERT constitute the minimal requirement for reconstituted in vitro
telomerase activity [53, 54]. The CR7 and H/ACA domains are required for stability and
localization of telomerase [55]. H/ACA motif consists of two hairpins connected by a short
single-stranded stretch, the H box, and a terminal ACA region [56] which is found in small
nucleolar and small Cajal body (CB) RNAs (snoRNAs and scaRNAs). H/ACA small nucleolar
ribonucleoprotein complex (H/ACA snoRNP) catalyzes pseudouridylation of small RNAs like
ribosomal RNA, which may serve to stabilize their conformation [57]. The H/ACA domain of
TR is essential for assembly into ribonucleoprotein (RNP) with four member H/ACA–RNP
complex which include the core heterotrimer (Dyskerin, NHP2, and NOP10) and a fourth
factor, GAR1 [56]. Dyskerin represents the catalytic subunit of H/ACA complex [57]. Major
function for the association of TR with dyskerin is its stabilization and nuclear retention.
However, no pseudouridylation of TR has been reported [58]. Structurally, dyskerin contains
a TruB domain that functions in eukaryotic ribosomal RNA processing. The TruB domain
consists of two motifs, TruB I and TruB II. In addition, it has two nuclear localization (NL)
signals, N-terminal and C-terminal, and the PUA, pseudouridine synthase and archaeosine
transglycosylase, domain involved in RNA modification [59]. Dyskerin and NOP10 form the
stable core to which GAR1 and NHP2 subsequently bind [60]. Mutations in these proteins
affect the stability of TR consequently affecting telomere synthesis and result in various human
diseases discussed in a later section of the chapter.
Although TR is transcribed by RNA polymerase II, it is not polyadenylated; instead, its 3′ end
is formed by exonucleolytic cleavage up to the boundary element formed by the H/ACA
domain, where further cleavage is prevented by dyskerin associated with RNA [61]. The
tetrameric complex of dyskerin, NOP10, NHP2, and the chaperone NAF1 associates with TR
cotranscriptionally and is essential for its accumulation [62]. The significance of this complex
formation is highlighted by a number of telomere length-associated disorders with mutations
in these factors which results in reduced levels of TR and thus telomerase activity [63].
TR also harbors specialized sequence elements in the terminal loop of its 3′ hairpin namely
BIO box, which stimulates TR stability by H/ACA RNP formation, and CAB box, which it
shares with the scaRNAs. CAB box is required for trafficking TR to the CB, where it receives
its 2,2,7-trimethyl guanosine (TMG) cap, and NAF1 is replaced by GAR1 [57, 64, 65].
TERT
Human TERT is a large protein consisting of 1133 amino acids and it is subdivided into four
distinct domains: (a) N-terminal extension (TEN), (b) TERT RNA-binding domain (TRBD), (c)
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the reverse transcriptase domain (RT), and (d) the C-terminal extension (CTE) [66]. TEN
domain is essential for telomerase activity and functions in proper localization and correct
positioning of its catalytic site on telomeric DNA [67]. The TRBD domain functions in telo‐
merase RNP assembly as well as RNA binding [68]. The RT domain of TERT forms the catalytic
center in telomerase complex and consists of seven universally conserved RT motifs [69–71].
RT domain can be divided into two putative subdomains namely the fingers and the palm
domains where fingers domain interacts with nucleic acid substrate while the palm domain
contains the catalytic site [72]. CTE possesses the thumb domain and is sequentially not
conserved among species [66]. CTE serves a critical role in catalytic activity and processivity
of telomerase [73].
TERT interacts with chaperones HSP90 and p23 as well as with AAA+ ATPases pontin and
reptin [74, 75]. HSP90 and p23 interact with active telomerase; however, reptin and pontin are
reported to interact with a pool of TERT, which is not assembled into active complex suggesting
their role in telomerase assembly [75]. In addition, reptin and pontin are known to interact
with dyskerin and are necessary for H/ACA RNP assembly, which is an essential step in TR
stability [75, 76].
TERT transcription and telomerase activity is highest in the S phase of the cell cycle [77], and
telomerase recruitment to telomeres has been shown to be restricted to the S phase [78, 79].
TERT interacts with two TR elements. The TRBD associates with CR4/5 region of TR and RT
domain of TERT associates with pseudoknot region of TR [53, 80]. The human telomerase RNP
purified from HEK293T cells overexpressing TERT and TR has been shown to be a dimeric
structure, which is around 28 nm in length [81]. Although many studies have suggested the
existence of multiple copies of dyskerin, NOP10, NHP2, and GAR1 with human telomerase
RNP, the presence of two catalytically active TERT has been controversial since its biological
significance is not clearly understood [82].
Telomerase activity in cells is limited by the levels of TERT protein (reported to be around 600
molecules/cell). All the other components of telomerase RNP are abundant [77, 83]. In normal
somatic cells, TERT expression is repressed epigenetically or due to lack of activating tran‐
scription factors such as MYC, NF-κB, NFAT, RAS/RAF pathway, Ets factor steroids, and HIF
[84]. Thus, transcriptional reactivation of TERT represents one of the major mechanisms
responsible for activating telomerase and thus achieving replicative immortality in cancers.
Recently, many cancers have been reported to harbor TERT promoter mutations resulting in
high TERT expression and telomerase activity [85]. This is further discussed in later sections
of the chapter.
2.3. Accessory proteins/complexes/factors for proper telomere maintenance
Regulator of telomere elongation helicase 1 (RTEL1)
RTEL1 is a DNA helicase, which contains N-terminal helicase domains and a C-terminal
extension [86]. TRF2 recruits RTEL1 to telomeres during S phase of cell cycle to assist t-loop
disassembly. RTEL1 is required for stability, protection, and elongation of telomeres [87].
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RTEL1 has also been shown to interact with proliferating cell nuclear antigen (PCNA) and this
interaction is important to prevent telomere fragility [87].
CST complex
The human CST complex consisting of CTC1, STN1, and TEN1 proteins plays a role in telomere
protection and DNA metabolism [88]. Each telomerase RNP is believed to add 50–60 nucleo‐
tides to most telomeres following a single initiation event [89]. The CST complex has been
proposed to set the upper limit of telomere elongation by binding to telomeric single-stranded
DNA (ssDNA) and displacing telomerase, once telomeric overhang has reached certain length
[90]. Study reported by Chen et al showed that CST competes with POT1–TPP1 for telomeric
DNA [90]. It terminates telomerase activity through primer sequestration and physical
association with the POT1–TPP1 subunits, which functions as a telomerase processivity factor
[91]. CST–telomeric-DNA binding increases during late S/G2 phase following telomerase
activity, concurrently with telomerase turn-off. Attenuation of CST enables excessive telomer‐
ase activity, fostering telomere elongation. It is suggested that through binding of the telo‐
merase-extended telomere, CST limits telomerase activity at individual telomeres to
approximately one binding and extension event per cell cycle.
Telomerase Cajal body protein 1 (TCAB1)
TCAB1 (encoded by gene WDR79) contains a proline-rich region and WD40 motif and is
localized in CBs. CBs have been shown to accumulate telomerase as well as associate with
telomeres [78]. TCAB1 has been demonstrated to be a component of active telomerase and is
necessary for the telomerase holoenzyme to accumulate in CB and thus regulate telomere
elongation [92]. TCAB1 interacts with CAB box motif of TR and functions in telomerase
assembly by driving telomerase to CB. Subsequent report by Stern et al showed that TCAB1
and CB are required for telomerase recruitment to telomeres independent of each other [93].
TERRA
TERRA functions as a negative regulator of telomere length. It is transcribed from subtelomeric
regions of telomeres that consist of UUAGGG repeats. TERRA may inhibit telomerase in cis
by directly binding to telomerase [94, 95].
3. Cross talk of telomere-associated proteins with cellular signaling
pathways
3.1. TAPs and DNA damage response
When the genomic DNA undergoes any damage such as single-strand DNA breaks, double-
strand breaks (DSBs), nicks, or chromosome fusions, cells activate DNA repair pathway
depending on the type of damage. During this process, cells seize to grow and initiate the
repair, and once the repair is completed growth resumes; otherwise, they undergo apoptosis.
Telomeres can also be sensed as breaks by cellular machinery. However, telomerase and
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shelterin complex cap the telomeres and thus maintain telomere integrity by inhibiting DNA-
damage-response pathway at telomeres. Further, some of these DNA repair proteins play an
essential role in telomere maintenance by directly associating with various TAPs. Recently,
these TAPs have been shown to play a role in DDR at locations distinct from telomeres. TRF1,
which is predominantly localized to telomeres, has been shown to interact with proteins
implicated in DNA damage response such as ATM and Mre11/Rad50/Nbs1 [96]. Further, it
has been shown that TRF1 is phosphorylated by Cdk1 and this form is incapable of binding
to telomeres [97]. It has been shown that this phosphorylated TRF1 in a telomere-independent
way facilitates end resection and homology repair (HR), activates G2/M checkpoint, and
enables cell survival following double-strand break induction [98]. TRF2 is known to prevent
activation of ATM-dependent DDR pathway at telomeres [26, 99, 100]. TRF2 has also been
shown to localize at DNA double-strand breaks during early stages (within 2 s) of cellular
response to DSBs and leaves those sites during repair processing [101]. Further reports
suggested that TRF2 may also participate in HR of the extra telomeric damaged DNA [102].
It has been shown that telomerase localizes to mitochondria and protects cancer cells from
nuclear DNA damage and apoptosis [103]. Further, TERT has also been shown to function in
DNA damage response pathway and in regulating histone-dependent chromatin remodeling
[104]. TR knockout mice display impaired DDR in response to damaging agents; however, the
effects are evident clearly in late-generation TR null mice, which show significant telomere
shortening and dysfunction [105, 106].
3.2. TAPs and NF-κB pathway
NF-κB transcription factors are key mediators of various cellular, inflammatory, and devel‐
opment pathways [107]. NF-κB family consists of five transcription factors namely RelA (p65),
RelB, c-Rel, and also includes p50 and p52 (processed from p105 and p100, respectively). Rel
family proteins possess REL homology domain, which harbors DNA-binding domain,
dimerization, and IκB-binding domain. NF-κB family members are held inactive in cytoplasm
by IκB family of proteins. Upon stimulation, IkB proteins are phosphorylated by IκB kinase
(IKK) complex and thus degraded or processed to produce active dimers, which can enter the
nucleus and activate the transcription response [107]. TAFs, which have been shown to
modulate NF-κB signaling, independent of their role at telomeres, include shelterin complex
protein RAP1 and telomerase complex protein TERT [108, 109].
A fraction of cytosolic RAP1 associates with functional IKK complex. RAP1 increases the
efficiency of IKK complex in phosphorylating p65 subunit at serine 536; however, it has no
effect on the degradation of IκBa inhibitory protein, thus functioning as an adaptor in the IKK
complex [110]. In line with this, it was recently shown that RAP1 regulates cytokine levels
followed by fine healing of corneal injury by effective modulation of NF-κB signaling [111].
Since RAP1 is also localized in cytoplasm, there are possibilities that it might function as an
adaptor in various other complexes under different stimuli.
TERT has also been shown to associate with p65 in the nuclear compartment, thus directly
regulating its transcriptional response. Akiyama et al demonstrated that TERT associates with
p65 to mediate its translocation to nucleus in multiple myeloma cells [112]. Recently, our group
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showed that TERT associates with p65 to directly affect its transcriptional output [113]. We
showed that TR-knockout mice are more resistant to inflammatory agent lipopolysaccharide
(LPS), which majorly functions by activating NF-κB pathway. Ectopic expression of TERT led
to increased proliferation of cancer cells as well as xenograft model, which could be abrogated
by inhibiting p65. Subsequently, another group showed that TERT regulates matrix metallo‐
proteinase (MMP) expression independently of telomerase activity via activation of NF-κB-
dependent transcription [114].
3.3. TAPs and WNT/β-catenin pathway
WNT pathway plays a key role in development processes like cell-fate determination,
progenitor cell proliferation, and cell polarity [115]. In canonical WNT pathway, WNT ligand
binds to its receptor leading to stabilization of β-catenin in the cytoplasm. Stabilized β-catenin
then enters nucleus to activate transcription through its interaction with TCF/Lef family
members. It further recruits chromatin remodelers like BRG1 to facilitate transcription.
TERT is the only TAP shown to modulate WNT pathway independent of telomeres and
telomerase catalytic activity. The first evidence demonstrating a link between TERT and WNT
pathway came from Choi et al who showed that knock in of catalytically inactive TERT in hair
follicle stem cells led to their proliferation [116]. Changes in gene expression as analyzed by
microarray, revealed differential expression of genes involved in development/morphogene‐
sis, signal transduction, and cytoskeleton/cell adhesion signaling pathways. Modulated gene
expression pattern strongly correlated with transcriptional program of MYC and WNT,
suggesting existence of a potential association of TERT with the WNT and MYC pathways.
Subsequently, Park et al demonstrated the first evidence of the direct regulation of Wnt/β-
catenin signaling by telomerase in mouse embryonic stem cells and Xenopus laevis embryos.
The study reported that TERT functions as a cofactor in the β-catenin transcriptional complex
through its interaction with Brg1, a chromatin-remodeling factor [117]. Ectopic expression of
TERT or catalytically inactive TERT led to the activation of WNT-dependent reporters in vitro
and in vivo, while chromatin immunoprecipitation assays uncovered TERT localization at
WNT target gene promoters. It was shown that TERT null mice display partially penetrant
homeotic transformation of vertebrae, due to the loss of 13th rib of one or both the vertebrae.
Recently, another group reported that TERT forms a complex with Brg1, together with
nucleostemin (NS), a nucleolar GTP-binding protein and/or its family member GNL3L and is
essential for maintenance of the tumor-initiating cell phenotype in human cancer cells [118].
3.4. TAPs and MYC
Recently, we reported that TERT regulates MYC transcription [119]. It is well known that MYC
directly regulates TERT transcription [120]. However, our study illuminated the existence of
a feed-forward loop between TERT and MYC in MYC-driven cancers such as lymphomas.
Using genetic and biochemical approaches, we showed that the absence of TERT delayed
MYC-dependent lymphomagenesis and strikingly, this effect was not observed when the RNA
component of telomerase, TR was removed. Using in vivo and in vitro approaches, we
established that TERT stabilizes MYC and thus results in increased MYC-dependent tran‐
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scriptional output. Furthermore, we showed that this effect of TERT on MYC stability was
independent of its catalytic activity. Mechanistically, we showed that TERT associates with
MYC, preventing its proteasomal degradation, thus stabilizing its protein levels [119].
3.5. TAPs and mitochondria
Among TAPs, TERT and TIN2 have been shown to be involved in regulating mitochondrial
activity. It has been shown that TERT translocates to mitochondria under certain stress
conditions [121–123]. Mitochondrial TERT binds to and protects mitochondrial DNA from
hydrogen peroxide-induced oxidative damage [103, 124]. Overexpression and knockdown
studies involving TERT in cancer cells have shown that the role of TERT in mitochondrial
pathway of apoptosis is independent of its catalytic activity [122, 125]. Interestingly, it has also
been shown that TERT functions as a reverse transcriptase in mitochondria using mitochon‐
drial tRNA as a template [126]. Furthermore, it has been shown that TERT can interact with
RNA component of mitochondrial RNA-processing endoribonuclease (RMRP) to form a
complex similar to RNA-dependent RNA polymerase (RdRP). This complex then affects gene
silencing at the post-transcriptional level [126].
TIN2 has also been shown to localize to mitochondria, where it results in altered mitochondrial
structure. The group showed that the reduction of TIN2 levels led to augmented mitochondrial
oxidative phosphorylation and reduced aerobic glycolysis in cancer cells [127].
3.6. TAPs and miscellaneous associations
Apart from the above-described associations of TAPs with cellular machinery, there are
various reports about many more interacting partners. TRF2 has been shown to function as a
transcriptional activator by directly binding to promoter of the angiogenic tyrosine kinase
platelet-derived growth factor receptor β (PDGFRβ). This study highlighted the angiogenic
role of TRF2 uncoupled from its telomere-capping role [128]. Telomerase was shown to
regulate rDNA transcription by directly associating with RNA polymerase I upon hyperpro‐
liferative stimuli such as during liver regeneration and Ras-induced hyperproliferation [129].
Figure 2 summarizes the role of telomere-interacting proteins in cross talk with cellular
signaling pathways.
4. Telomeres and TAPs in human diseases: Telomeropathies
Telomeres shorten with each cell division. When telomeres become excessively short, they lose
their protective role and activate a DNA damaging signal response resulting in genomic
instability, cell cycle arrest, and senescence. TAPs play an essential role in maintaining
telomere length, and genetic mutations affecting their activity can result in telomere dysfunc‐
tion. This manifests into a wide variety of diseases collectively named as “telomeropathies”
or “telomere syndromes”, which exhibit impaired telomere maintenance.
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4.1. Telomere-shortening syndromes
Inherited mutations, which hamper telomerase or telomere maintenance genes, result in
progressive shortening of telomeres. Telomere shortening has major impact on highly
proliferating tissues, such as bone marrow, where stem cells reach senescence stage and organ
failure might ensue. Clinical conditions associated with shortened telomeres may be very
different. This may be partly due to genetic anticipation since telomere length is inherited [63].
4.1.1. Dyskeratosis congenita
Dyskeratosis congenita (DC) arises primarily due to bone marrow failure and is associated
with a diagnostic triad of oral leukoplakia, skin hyperpigmentation, nail dystrophy, and other
manifestations. Dyskerin (encoded by DKC1), which is an essential component of telomerase
enzyme in vivo, was the first gene identified as a cause of DC, and was thus named after this
syndrome. DC is a heterogeneous disease showing all modes of inheritance. To date, 11 genes
have been associated with DC. These include genes encoding products involved in telomere
elongating enzyme, telomerase components (TERT and TR), telomerase stability (dyskerin,
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NOP10, NHP2), telomerase recruitment (TIN2 and TPP1), telomerase trafficking (TCAB1),
telomerase docking (CTC1), and telomere replication (RTEL1) [130].
Figure 3 shows schematic representation of telomere-interacting proteins with domains and
positions of reported germ-line mutations, which result in various forms of DC.
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Figure 3. Schematic representation showing protein structure and localization of reported mutations in telomere asso‐
ciated proteins. The information is adapted from Espinoza et al [144].
Recently poly(A)-specific ribonuclease (PARN) gene mutations have been reported in a
subgroup of patients with DC wherein PARN deficiency results in reduced stability of several
key TAPs (dyskerin, TRF1, RTEL1, and TR) and specifically leads to telomere attrition [131].
Almost all modes of inheritance have been reported in DC, which include autosomal recessive,
autosomal dominant, and X-linked. Based on functional relevance of mutated proteins and
their penetrance, clinically diverse variant manifestations of DC are reported.
Calado et al reported a study of five families who were suffering from liver disease (familial
liver cirrhosis) in combination with hematologic and autoimmune disorders [132]. They
analyzed the mutations associated with the disease and found rare loss of function mutations
in TERT or TR (3.7% vs 0.8%). Hoyeraal–Hreidarsson syndrome (HHS) is associated with
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intrauterine growth retardation (IUGR), microcephaly, cerebellar hypoplasia, and thrombo‐
cytopenia along with various nonspecific enteropathies. HHS patients are also found to harbor
DC mucocutaneous triad in adulthood. Detailed analysis revealed mutations in DKC1, TIN2
along with some cases showing autosomal recessive mutations in TERT, NHP2, NOP10, TPP1,
and RTEL1 genes [133, 134]. Revesz syndrome (RS) is associated with various disease mani‐
festations mainly bilateral exudative retinopathy. Other symptoms reported include IUGR,
intracranial calcifications, developmental delay, and nail dystrophy in different cases, which
were highly overlapping with DC symptoms. It was discovered that RS patients have short
telomeres and harbor germ-line mutations in TINF2 gene [135]. Coats plus syndrome (CCS) is
a rare recessive disorder that is characterized by intracranial calcifications, hematological
abnormalities, and retinal vascular defects. CCS patients display shortened telomeres indicat‐
ing telomere dysfunction as a major cause. Missense mutations in CTC1 gene whose protein
is a part of CST complex has been reported to occur in CCS patients [136]. HHS, RS, and CCS
represent severe forms of DC.
About 10% of DC patients develop cancer at a very young age. Various DC families display
an increased incidence of acute myeloid leukemia and myelodysplastic syndrome [137].
Spontaneous reversion to the functional TR allele in hematopoietic stem cells of haploinsuffi‐
cient DC patients has been observed predisposing them to hematological disorders. The
mechanism behind high cancer incidence, in spite of short telomeres that should have cancer-
protecting effect, remains largely unexplained. The only proposed mechanism is genomic
instability due to fusion of chromosome ends by NHEJ as has been observed in mutation
carriers and in TR-knockout mice [138].
4.1.2. Pulmonary fibrosis
Idiopathic pulmonary fibrosis (IPF) disease is characterized by progressive lung scarring and
fibrotic changes. The disease is associated with abnormal telomere maintenance and is an
attenuated form where fibrosis develops with cumulative age-related changes. This disease
arises from mutations in genes encoding TERT and TR leading to reduced telomerase activity
and subsequently shorter telomeres, resulting in impaired growth of lung stem cells [139].
Surprisingly, short telomeres have been detected in IPF patients with intact telomerase genes,
indicating that IPF may develop in people who have short telomere lengths [140]. This study
also showed the development of liver cirrhosis in 3% of sporadic IPF patients, demonstrating
a complication of telomere-mediated disease outside the lung even in the absence of telomerase
mutations. Also, increased incidence of insulin-dependent diabetes is detected in IPF patients
[141]. Short telomeres have been shown to cause insulin secretion defects and glucose intol‐
erance in telomerase-deficient mice [142].
4.1.3. Bone marrow failure
Many bone marrow failure disease cases have been linked to telomere biology. Mutations in
telomeric proteins can lead to accelerated telomere attrition in hematopoietic compartment
leading to bone marrow failure. The most common gene associated with bone marrow failure
is TERT, which generally harbors point mutations in its gene [143, 144].
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4.2. Role of TAPs in cancer
The role of TAPs in cancer development is well known. People with long telomeres are at a
greater genetic risk of developing cancers [145]. Thus, examining the role of telomere proteins
in cancer holds immense prognostic, diagnostic, and therapeutic value.
4.2.1. Shelterin proteins and cancer
The shelterin complex member POT1 was found to be somatically inactivated in chronic
lymphocytic  leukemia where it  led to  telomere deprotection and length extension [146].
Recently, two studies reported occurrence of rare, germ-line variants in POT1, making them
susceptible to the development of familial melanoma [145]. In these cohorts, carrier individ‐
uals displayed significantly longer and more fragile telomeres than controls, and in some
cases developed cancer in other tissues along with melanoma. Molecular and functional
analysis showed that some of the variants abrogate the binding of POT1 to ssDNA, thus
raising the possibility that carriers are predisposed to malignancy via telomere uncapping
and  a  more  permissive  extension  of  chromosome  ends.  However,  the  exact  biological
mechanism needs further investigation. Mutation in RAP1, another shelterin protein member
was reported in a melanoma cohort. RAP1 is involved in negative regulation of telomere
length and functions by repressing homology-directed repair [147]. Mutations were report‐
ed to occur in TRF1-interacting region of RAP1. This loss of interaction with shelterin may
increase the risk of cancer development.
Germ-line mutations affecting other proteins that interact with shelterin complex members
and increase cancer risk have also been reported. For example, ku80, which interacts with
RAP1 and PARP1, which in turn interacts with TRF2, has been found to be associated with
diffuse large B-cell lymphomas.
4.2.2. Telomerase and cancer
Telomerase  activity  is  essential  for  immortalization.  Thus,  targeting  telomerase  activity
represents an attractive approach for both cancer diagnosis and treatment [148,  149].  As
described  previously,  TERT  is  the  limiting  factor  for  telomerase  activity.  Therefore,  its
reactivation mechanisms hold great significance in understanding the development of cancer
and thus designing targeted therapies.
Two hot-spot mutations in the TERT promoter, -228 C>T and -250 C>T, were recently reported
to  occur  at  high  frequency  in  several  solid  tumors,  for  example:  melanoma,  gliomas,
carcinoma of bladder, urothelial cancer, thyroid and squamous cell carcinoma of the tongue,
as well as in liposarcomas and hepatocellular carcinomas, which have relatively low rates of
self-renewal [85, 150–153]. It was recently shown that TERT promoter mutations create novel
binding sites for GABP, which belongs to Ets family of transcription factors [154]. These
mutations have strong clinical implications with worse prognosis and poor survival, and thus
may represent a novel therapeutic target [153].
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TERT promoter mutation in skin cancers
Stem cells differentiate into normal somatic cells and as a consequence repress TERT tran‐
scription. Upon subsequent cell division, progressive telomere shortening occurs due to lack
of telomerase activity. This acts as a barrier for tumor development and progression. Skin
epidermal cells are highly differentiated cells, possess short telomeres, and are thus capable
of undergoing limited proliferation [155]. However, in melanoma, increased telomerase
activity is reported and this has been associated with high proliferation rate and early meta‐
stasis [156, 157].
High frequency of TERT promoter mutations has been reported in familial and sporadic
melanoma (about 29–73%) [150, 151]. In primary cutaneous melanoma, TERT promoter
mutations were found to be associated with BRAFV600E mutations, worse prognostic features,
and shorter disease-free and overall survival [158, 159]. TERT promoter mutations have also
been reported to be common in nonmelanoma skin cancer ranging from 39 to 74% in sporadic
basal cell carcinoma and up to 50% mutation frequency in squamous cell carcinoma [158, 160,
161]. Various studies have assessed the association between telomere length and risk of
developing skin cancer [162]. Some reports suggest no association between telomere length in
peripheral blood leukocytes (PBL) and risk of nonmelanoma skin cancer [163]. On the contrary,
other authors have reported that longer telomeres in PBL are protective for certain skin cancer
types [162].
TERT promoter mutations in central nervous system (CNS) tumors
Within CNS tumors, gliomas have been shown to possess the highest frequency of TERT
promoter mutations, while medulloblastoma and meningioma show lower frequencies [164].
Within gliomas, the percentage of cases with TERT promoter mutations varies depending on
the histopathological type of tumor. TERT promoter mutations are reported in a large number
of cases of glioblastoma multiforme (GBM), which is the most frequent and aggressive form
of glioma, and in oligodendrogliomas, in contrast to astrocytoma and ependymoma, where
only a small percentage of the tumors possess such mutations [159, 164]. Furthermore, the
frequency of TERT promoter mutations in oligoastrocytomas, gliomas with a mixed origin, is
in between that of oligodendrogliomas and astrocytomas [152]. These findings are consistent
with the reported data on telomerase activity in gliomas, which is significantly higher in GBM
(50–89%) and oligodendrogliomas (75–100%) than in astrocytomas (0–45%) [165–167].
Some studies also reported an association between single-nucleotide polymorphisms (SNPs)
in the TERT gene and an increased risk of glioma development [168, 169].
TERT promoter mutations in other cancers
Telomerase role in bladder carcinoma (BC) has been reported. In majority of BC tumor samples,
telomerase activity was detected, while it was absent in the respective normal parallel samples
[170, 171]. In some reports, telomerase activity was associated with lower grade and lower
stage BC [170, 172]. Other studies showed that both telomerase activity and telomerase
expression are associated with more advanced and higher grade of cancers [171, 173]. Pre‐
liminary evidence obtained in cell lines suggests that BC might have TERT promoter mutations
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[150]. TERT promoter mutations are also frequently detected in BC cell lines, with a prevalence
ranging from 47 to 85%. These results have clearly shown that TERT promoter mutations
represent one of the most common genetic events, perhaps the most frequent, in BC [85].
TERT promoter mutations also occur at high frequency in other cancer types, for example:
hepatocellular carcinoma (56%), several soft tissue tumors histotypes (e.g., 93% in atypical
fibroxanthoma, 79% in myxoid liposarcoma, and 76% in pleomorphic dermal sarcoma) and
carcinoma of the renal pelvis (64%). Tumor histotypes with intermediate frequencies of TERT
promoter mutations comprise laryngeal carcinoma (27%) and clear cell carcinoma of the ovary
(16%) [174]. TERT promoter mutations are not frequently found in leukemias and colorectal
cancers [174].
The high prevalence of TERT promoter mutations suggests the significance of telomere
maintenance in cancers. Clinically, TERT promoter mutations represent a potential biomarker
in cancer prognosis. Furthermore, TERT promoter mutations also serve as an attractive
therapeutic target since they occur specifically in cancer cells and are absent in surrounding
healthy tissues.
5. Conclusion
Telomeres are organized into highly specialized structures at chromosome ends. Telomerase
and shelterin plays a role in telomere homeostasis. Along with telomere maintenance,
telomere-associated proteins also play a significant role in various cell-signaling pathways.
The significance and implication of telomerase and shelterin in human diseases have also been
firmly established in various models of degenerative diseases. In cancer, telomerase dysfunc‐
tion has been identified as a critical step for immortalization, although the underlying
mechanisms are unclear. The recent identification of telomerase promoter mutations has
stimulated research, following which numerous studies have reported similar alterations in
various cancer models. In several relevant cancer types, telomerase promoter mutations seem
to represent a new biomarker for prognosis with potential applications in presurgical diagnosis
and in the monitoring of patients. Mechanisms regulating telomerase promoter mutations also
hold immense therapeutic value since they occur specifically in cancers.
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